Literature DB >> 34321857

Gastrointestinal cytomegalovirus disease secondary to measles in an immunocompetent infant.

Chao-Ming Hung1, Po-Huang Lee2, Hui-Ming Lee1, Chong-Chi Chiu1.   

Abstract

Yang et al reported an immunocompetent infant with gastrointestinal cytomegalovirus disease secondary to measles infection. We express our opinion about the diagnosis and treatment of this rare disease. ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.

Entities:  

Keywords:  Diarrhea; Gastrointestinal cytomegalovirus disease; Immunocompetent infant; Measles; Rare disease

Mesh:

Year:  2021        PMID: 34321857      PMCID: PMC8291027          DOI: 10.3748/wjg.v27.i25.3948

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


Core Tip: We want to discuss the diagnosis and treatment issues in the rare gastrointestinal cytomegalovirus disease secondary to measles infection.

TO THE EDITOR

We read with interest the study by Yang et al[1]. They highlighted the differential diagnosis and pathological features of gastrointestinal cytomegalovirus (CMV) infection in a 9-mo-old boy. In our opinion, some concepts about the diagnosis and treatment should be emphasized. Measles leads to the morbidity of diarrhea and may cause dehydration and secondary malnutrition[2]. Its incidence is about 8%[3]. Instead, uncontrolled diarrhea caused by postnatally infected CMV in immunocompetent infants has been rarely reported. Differential diagnosis of the diarrhea cause is a great challenge to pediatric physicians, especially when most infants with neither endoscopic exam nor pathological confirmation of gastrointestinal CMV infection. To our knowledge, most measles-infected patients only need supportive management, including fluid supply, antipyretics, and prevention of superimposed bacterial infections. There is no specific antiviral therapy. Although the efficacy in preventing and treating CMV infection has been proven in transplant recipients, Ganciclovir has not been supported effectively in treating pediatric patients[4]. It has been administered to infants with congenital infection[5] and cholestasis[6]; however, there are no controlled studies to support its effectiveness[5]. Fortunately, this 9-mo-old boy recovered completely after intravenous Ganciclovir administration with no evident side effects. Low serum vitamin A level has been a common situation among children, even in some developed countries, e.g., United States. Significant lower levels were encountered in critically ill children. Vitamin A deficit hinders the recovery course and increases measles-related complications. Besides, measles infection would further deteriorate the deficit of vitamin A serum concentration and aggravate the severity of xerophthalmia[7]. In a randomized controlled trial, lower morbidities and mortality have been found in measles-infected children after vitamin A supplement[8]. Thus, the World Health Organization recommended vitamin A administration to all acute measles-infected children[9]. We also suggest the same management to this 9-mo-old boy during the treatment course. Vaccination is the most effective strategy to interrupt this virus transmission because it could lead to herd immunity, which must be maintained above 85% to 95%[10]. Thus, encouragement of measles vaccination is essential to avoid the occurrence of similar episodes.
  10 in total

Review 1.  Summary and conclusions: measles elimination meeting, 16-17 March 2000.

Authors:  Samuel L Katz; Alan R Hinman
Journal:  J Infect Dis       Date:  2004-05-01       Impact factor: 5.226

2.  A randomized, controlled trial of vitamin A in children with severe measles.

Authors:  G D Hussey; M Klein
Journal:  N Engl J Med       Date:  1990-07-19       Impact factor: 91.245

3.  Ganciclovir prophylaxis for cytomegalovirus infection in pediatric allogeneic bone marrow transplant recipients.

Authors:  C Canpolat; S Culbert; M Gardner; E Whimbey; J Tarrand; K W Chan
Journal:  Bone Marrow Transplant       Date:  1996-04       Impact factor: 5.483

4.  Ganciclovir treatment in infants with cytomegalovirus infection and cholestasis.

Authors:  Björn Fischler; Thomas H Casswall; Petter Malmborg; Antal Nemeth
Journal:  J Pediatr Gastroenterol Nutr       Date:  2002-02       Impact factor: 2.839

5.  Ganciclovir treatment of symptomatic congenital cytomegalovirus infection: results of a phase II study. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group.

Authors:  R J Whitley; G Cloud; W Gruber; G A Storch; G J Demmler; R F Jacobs; W Dankner; S A Spector; S Starr; R F Pass; S Stagno; W J Britt; C Alford; S Soong; X J Zhou; L Sherrill; J M FitzGerald; J P Sommadossi
Journal:  J Infect Dis       Date:  1997-05       Impact factor: 5.226

Review 6.  Vitamin A for treating measles in children.

Authors:  Y Huiming; W Chaomin; M Meng
Journal:  Cochrane Database Syst Rev       Date:  2005-10-19

Review 7.  Vitamin A supplements for preventing mortality, illness, and blindness in children aged under 5: systematic review and meta-analysis.

Authors:  Evan Mayo-Wilson; Aamer Imdad; Kurt Herzer; Mohammad Yawar Yakoob; Zulfiqar A Bhutta
Journal:  BMJ       Date:  2011-08-25

Review 8.  Available studies fail to provide strong evidence of increased risk of diarrhea mortality due to measles in the period 4-26 weeks after measles rash onset.

Authors:  Bianca D Jackson; Robert E Black
Journal:  BMC Public Health       Date:  2017-11-07       Impact factor: 3.295

9.  Gastrointestinal cytomegalovirus disease secondary to measles in an immunocompetent infant: A case report.

Authors:  Qing-Hua Yang; Xiao-Peng Ma; Dong-Ling Dai; Da-Ming Bai; Yu Zou; Si-Xi Liu; Jian-Ming Song
Journal:  World J Gastroenterol       Date:  2021-04-21       Impact factor: 5.742

Review 10.  Measles: An Overview of a Re-Emerging Disease in Children and Immunocompromised Patients.

Authors:  Andrea Misin; Roberta Maria Antonello; Stefano Di Bella; Giuseppina Campisciano; Nunzia Zanotta; Daniele Roberto Giacobbe; Manola Comar; Roberto Luzzati
Journal:  Microorganisms       Date:  2020-02-18
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.